Luspatercept is a recombinant fusion protein belonging to the activin receptor type IIB antagonist class, used to treat specific types of anemia by stimulating erythropoiesis in conditions such as chronic… Read more
Luspatercept is a recombinant fusion protein belonging to the activin receptor type IIB antagonist class, used to treat specific types of anemia by stimulating erythropoiesis in conditions such as chronic kidney disease and sickle cell disease. As a therapeutic biologic comprising a synthetic human extracellular domain fused with an immunoglobulin G1 Fc region, it requires rigorous analytical oversight during production. This category provides access to high-quality reference standards for Luspatercept API, as well as its related impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories performing impurity profiling, method validation, and routine quality control. Utilizing these characterized compounds ensures accuracy in quantification and identification, allowing for compliance with regulatory standards throughout the drug development and manufacturing lifecycle for this complex biologic agent.